Monthly injection reduces migraine frequency without major side effects
"Progress, but not a panacea." So proclaims an editorial in journal JAMA
on Aimovig, a first-of-its-kind drug purported to prevent chronic migraines without many side effects that was on Thursday approved by the FDA. The drug from Amgen and Novartis, and similar ones in their final stages, "...